USBC, INC. USBC

USBC, Inc. (USBC) completed the divestiture of its legacy sensor technology business. Divestiture of legacy sensor technology business is a major strategic move enabling USBC to refocus on core operations and improve long-term financial performance.

USBC, INC. (USBC) has regained full compliance with NYSE American listing standards after addressing prior deficiencies. Regaining full NYSE American compliance eliminates delisting risk and enhances investor confidence in USBC's market stability.

USBC, INC. has entered into a definitive agreement with Uphold and Vast Bank to further its tokenized bank deposit initiative. This collaboration aims to enhance the accessibility and efficiency of banking services through tokenization, potentially transforming traditional banking practices. The partnership is expected to leverage the strengths of each entity to innovate in the financial sector. The partnership with Uphold and Vast Bank is a significant strategic move that could alter USBC's market positioning and investor sentiment.

Know Labs, Inc. has successfully closed a strategic acquisition valued at $125 million, led by Greg Kidd. This acquisition is expected to enhance Know Labs' capabilities and market position, aligning with its growth strategy in the health technology sector. The acquisition is a significant strategic move that could enhance Know Labs' competitive positioning and market dynamics.

Know Labs, Inc. has successfully closed a $100 million strategic acquisition, a move aimed at enhancing its market position and expanding its technological capabilities. This acquisition is expected to bolster the company's growth trajectory and strengthen its competitive edge in the industry. The acquisition is a significant strategic move that could alter the company's trajectory and investor sentiment.

Know Labs, Inc. (KNW) reminds stockholders to vote ahead of the Special Meeting on July 24, 2025. Stockholders as of June 20, 2025, are encouraged to vote 'For' each proposal using the provided methods. Voting can be done online or by phone, with a deadline of July 23, 2025, at 11:59 p.m. Eastern time. The company specializes in non-invasive health monitoring solutions, with a focus on a non-invasive glucose monitor pending FDA clearance. The upcoming Special Meeting and proposals may influence stockholder sentiment and operational direction, but the overall impact is expected to be limited.

Know Labs, Inc. has entered an agreement with Greg Kidd's Goldeneye 1995 LLC for Kidd to acquire a controlling interest in the company. Following the transaction, Kidd will become CEO and Chairman, implementing a Bitcoin treasury strategy to enhance the company's financial position. The deal involves acquiring shares through a combination of 1,000 Bitcoin and cash to address existing debt and provide working capital. The transaction is expected to close in Q3 2025, pending shareholder approval. Founder Ron Erickson will transition to Vice Chairman while continuing research in non-invasive medical technology. The acquisition and introduction of a Bitcoin treasury strategy are significant strategic moves that could substantially alter the company's financial trajectory and investor sentiment.

Know Labs, Inc. (KNW) has developed a patented Radio Frequency Dielectric Spectroscopy (RFDS) sensor technology that non-invasively measures pH levels in real time. This innovation has significant applications in medical diagnostics, pharmaceutical manufacturing, and food safety. The research has been submitted for peer review and highlights the sensor's ability to detect pH changes without direct contact with the liquid. The company aims to leverage this technology through its Know Labs Technology Licensing (KTL) program, promoting its use across various industries. CEO Ron Erickson emphasizes the potential for low-cost, high-quality results in diverse applications. The introduction of a non-invasive pH measurement technology could significantly enhance medical diagnostics and food safety, impacting the company's market position.

Know Labs, Inc. (KNW) will attend the 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Amsterdam from March 19-22, 2025, to discuss its non-invasive blood glucose monitor and explore collaboration opportunities with leaders in diabetes management. The company recently announced Know Labs Technology Licensing (KTL) to facilitate partnerships and licensing for its Radio Frequency Dielectric Spectroscopy (RFDS) technology, which aims to provide accessible real-time blood glucose monitoring. FDA clearance is required for the glucose monitor's market introduction. The company's participation in a major diabetes conference and the focus on strategic partnerships could significantly impact its market positioning and product development.

Know Labs, Inc. announced that the NYSE Regulation has lifted the trading suspension of its common stock, which will resume trading on March 5, 2025, under the symbol 'KNW'. The company is still working to regain compliance with NYSE American's continued listing standards by March 27, 2026, and failure to do so may result in delisting proceedings. Know Labs specializes in Radio Frequency Dielectric Spectroscopy technology, aiming to develop non-invasive glucose monitoring devices among other applications. Lifting the trading suspension and the company's ongoing compliance efforts are significant for its market performance and investor sentiment.

Know Labs, Inc. has received approval to begin trading on the OTCQB Market, enhancing its visibility and accessibility to investors. This move is expected to facilitate greater liquidity and attract a broader range of investors, potentially supporting the company's growth initiatives. Trading on the OTCQB Market is likely to significantly enhance investor access and liquidity, impacting the company's future performance.

Know Labs, Inc. announced the cancellation of its Special Meeting of Stockholders scheduled for March 7, 2025, which was intended to seek approval for a reverse stock split. The cancellation follows the company's announcement of a 1 for 40 reverse stock split that became effective on February 19, 2025, and did not require stockholder approval. Know Labs focuses on radio frequency dielectric spectroscopy technology, with applications including a non-invasive glucose monitor pending FDA clearance. The cancellation of the meeting and the reverse stock split may moderately influence investor sentiment and operational aspects but are not expected to fundamentally alter the company's trajectory.

Know Labs, Inc. announced a 1 for 40 reverse stock split effective February 19, 2025, to regain compliance with NYSE American listing criteria after its stock price fell below $0.10. The company's shares will temporarily trade under the symbol 'KNWND' for 20 days before reverting to 'KNWN'. The reverse split was approved by the Board of Directors amid ongoing delisting proceedings. CEO Ron Erickson emphasized the importance of maintaining the NYSE listing and expressed confidence in the company's technology and upcoming revenue from its licensing division. Know Labs is focused on developing non-invasive glucose monitoring technology, pending FDA clearance. The reverse stock split is a significant strategic move aimed at maintaining the company's NYSE listing, which could greatly influence investor sentiment and market performance.

Know Labs, Inc. (OTC: KNWN) reported a net loss of $4.67 million for Q1 FY 2025, a 35.4% increase from the previous year. Earnings per share remained unchanged at a loss of $0.04. The company reduced research and development expenses by 46.1% to $802,000 and lowered selling, general, and administrative expenses by 2.0% to $1.97 million. Cash and cash equivalents decreased to $1.03 million from $3.11 million. Know Labs plans to seek additional funding and is addressing negative shareholder equity of $3.91 million. A conference call will be held to discuss results and business updates. The increase in net loss and ongoing funding challenges may moderately influence financial performance and investor sentiment.

Know Labs Technology Licensing (KTL) has announced a formalized engagement with clients to advance its technology solutions. This initiative aims to enhance collaboration and drive innovation in the healthcare sector, leveraging KTL's proprietary technology for improved diagnostic capabilities. The company is focused on expanding its market presence and fostering partnerships that align with its strategic goals. Formalized client engagement is expected to significantly enhance Know Labs' market positioning and revenue potential.

Know Labs, Inc. (KNWN) has filed an appeal against the NYSE American's decision to delist the company due to its stock price falling below $0.10. While the appeal is pending, trading will continue on the OTC market under the symbol 'KNWN'. CEO Ron Erickson expressed optimism about the company's future, highlighting recent advancements in technology and a new licensing program aimed at generating revenue. The company is focused on developing non-invasive diagnostics, particularly for blood glucose monitoring, pending FDA clearance. The delisting and transition to OTC trading may moderately influence investor sentiment and operational aspects, but the company's ongoing technology development and licensing efforts could balance the impact.

Know Labs, Inc. (NYSE American: KNW) announced it is appealing the NYSE's decision to delist its stock due to a bid price below $0.10. The stock is currently suspended from trading on the NYSE American and is now trading under the symbol 'KNWN' on the OTC Markets. CEO Ron Erickson expressed confidence in the company's future despite these challenges, highlighting ongoing advancements in their technology and a new licensing program. Know Labs focuses on non-invasive diagnostics, particularly a glucose monitoring device pending FDA clearance. The delisting proceedings and transition to OTC trading may moderately influence investor sentiment and operational aspects but do not fundamentally alter the company's long-term trajectory.

Know Labs, Inc. has launched Know Labs Technology Licensing (KTL), a new initiative aimed at commercializing its proprietary technology. KTL will focus on licensing the company's innovative solutions to various industries, enhancing its revenue streams and market reach. This strategic move is expected to leverage Know Labs' advancements in technology and expand its footprint in the market. The launch of KTL represents a significant strategic move that could enhance revenue and market positioning.

Know Labs, Inc. has announced that NYSE American has accepted their plan to regain compliance. The acceptance of the compliance plan may have a moderately noticeable influence on the company's financial performance and competitive positioning.

Know Labs provides an overview of FY2024 10-K annual report. The annual report may affect financial performance and competitive positioning.

Know Labs, Inc. received an audit opinion with a going concern explanation in its financial statements for the year ended September 30, 2024. The audit opinion with a going concern explanation may moderately influence the company's financial performance and market sentiment.

Know Labs, Inc. reported a net loss of $16.58 million in FY2024, an increase from the previous year. The company's R&D expenses decreased, while selling and administrative expenses increased. Cash and cash equivalents decreased, but the company believes it has enough cash to operate through February 2025. Financial results show a mix of positive and negative indicators, with potential impact on the company's financial performance and operations.

Know Labs, Inc. announced two new executives, John Cronin and Dominic Klyve, to lead technology development and secure strategic partnerships. The addition of experienced executives to drive technology development and strategic partnerships is expected to have a significant impact on Know Labs' future growth and market performance.

Know Labs, Inc. partners with The Stanbridge Group to embed sensor technology in automobile steering wheels to detect blood alcohol levels and prevent impaired driving. The partnership with The Stanbridge Group to embed sensor technology in steering wheels to prevent impaired driving has the potential to significantly impact Know Labs, Inc.'s future market performance and competitive positioning.

Know Labs, Inc. received a notice of noncompliance from NYSE American for not meeting listing standards. The company must submit a compliance plan by October 27, 2024. The potential impact on Know Labs' future and market performance is moderately noticeable due to the need to address noncompliance issues and implement a plan for compliance.

Know Labs, Inc. published a study in IEEE Sensors Journal validating their RF dielectric sensor for non-invasive blood glucose monitoring. The publication of the study in a prestigious journal and the potential impact on non-invasive diabetes management solutions suggest a significant influence on the company's future and market performance.

Know Labs, Inc. announced a $1.655 million public offering, selling 6,365,385 Units at $0.26 per unit. The proceeds will be used for product development, clinical studies, and working capital. The public offering and use of proceeds are significant strategic moves that could alter the company's trajectory and investor sentiment.

Know Labs, Inc. reported a net loss of $4.10 million in Q3 FY 2024, with a decrease in research and development expenses but an increase in selling, general, and administrative expenses. The company closed a public offering of $3.45 million to ensure operations until December 31, 2024. The financial results and funding initiatives are expected to moderately influence the company's future performance and market sentiment.

Know Labs, Inc. closed a $3.445 million public offering to accelerate development of its non-invasive medical diagnostics technology, including a wearable continuous glucose monitoring device. The successful public offering will provide significant financial resources to advance product development efforts and clinical validation studies, potentially altering the company's trajectory.

Know Labs, Inc. priced a public offering of 13,250,000 units at $0.26 per unit, totaling $3.445 million in gross proceeds. The public offering will provide significant funding for product development, clinical studies, and general expenses, potentially impacting the company's future growth and market performance.